Aurora BioPharma, Inc. to Attend J.P. Morgan Healthcare Conference, and Present at OneMedForum and Biotech Showcase
CAMBRIDGE, MA - January 4, 2016 - Aurora BioPharma, Inc. announces its CEO, Robert Brooks, will attend the 34th Annual J.P. Morgan Healthcare Conference, and present at the following events in San Francisco:
Event: 9th Annual OneMedForum January 11 - 13th 2016
Date: Tuesday, January 12th
Time: 12:00 pm to 12:20 pm PST
Location: Club OneMed, Kensington Park Hotel at 450 Post Street
Event: Biotech Showcase January 11 - 13th 2016
Date: Wednesday, January 13th
Time: 9:15 am to 9:30 am PST
Location: Track: A-Hearst, Parc 55 Hotel at 55 Cyril Magnin Street
About Aurora BioPharma, Inc.
Aurora is a biotechnology company based in Cambridge, Massachusetts commercializing cutting-edge cancer immunotherapy in FDA human clinical trials. The Company has completed two Phase 1 trials in genetically reprogrammed CAR T cell therapy in solid tumor, Glioblastoma and Sarcoma. The National Cancer Institute estimates about 25,000 people are diagnosed annually with Glioblastoma brain cancer. Most notably, that included Vice President Joe Biden's son, Beau Biden, and Senator Ted Kennedy. A Phase 1 trial in Glioblastoma with Aurora's CAR T agent AU-105 met its endpoints of safety and anti-Tumor Efficacy, in addition to achieving a very promising signal of double median overall survival. Aurora is planning a randomized multi-site Phase II trial its CAR T Cell therapy AU105 in Early Diagnosed Glioblastoma, and a Phase I/II trial of Recurrent Glioblastoma with the world's first CAR T cell therapy delivered via intracranial injection. Osteosarcoma is the most common type of bone cancer in Children and Adolescents. Even after radical amputation of a limb and chemotherapy, survival is poor. A Phase 1 trial in Sarcoma and Osteosarcoma with Aurora's CAR T agent AU-105 met its endpoints of safety, with strong signs of Tumor killing Efficacy. Aurora is planning a Phase II trial of its CAR T Cell therapy AU105 in Osteosarcoma. The Company also has an equity interest in MedVax Technologies, Inc., its p53 DC cancer vaccine MX-225 has completed two FDA Phase II clinical trials, in Small Cell Lung Cancer, and the company is planning a combination trial with a PD-1 antibody in lung cancer with a major pharmaceutical company; and MX-225 is also in a Phase II combination trial in breast cancer with Indoximod, an IDO inhibitor from NewLink Genetics.
Over the past 9 years, OneMed Forums have featured over 300 experts as panelists and contributors and almost 500 presenting CEO's. This large network of experts include venture capital firms, angel groups, associations, and incubators. Organized by OneMed Research, the conferences serve as an opportunity for corporate leaders and investors to interact and form relationships beneficial to the healthcare community.
About Biotech Showcase™
The Biotech Showcase™ conference is one of the largest annual international healthcare conferences and will run parallel to the JP Morgan Healthcare Conference (San Francisco, January 11-14, 2016). Investors and biopharmaceutical executives from around the world gather in San Francisco during this second week of January which is widely viewed as setting the tone for the coming year.
This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For media inquiries, please contact:
VP, Business Development & Public Relations
Aurora BioPharma, Inc.
Harvard Square, One Mifflin Place, Suite 400
Cambridge, MA 02138
Tel: (617) 674-7718 - Fax: (617) 674-7701
Ingraham Building, 25 SE 2nd Avenue, Suite 504
Miami, FL 33131
Tel: (305) 371-2301 - Fax: (305) 371-2304
email@example.com - www.aurorabiopharma.net
- New Paradigm in Cancer Immunotherapy -
Source: Aurora BioPharma, Inc.